Key Takeaways Microdosing could theoretically reduce peak-to-trough ratios by 28-38%, potentially minimizing side effects Successful precedents exist with insulin and growth hormone therapies using similar principles Mathematical models suggest maintained efficacy (~75-100%) with appropriate dose adjustments No clinical trials have validated microdosing for GLP-1 agonists - all evidence is theoretical or anecdotal 55% of microdosers make decisions without physician consultation, raising safety concerns What Is Retatrutide Microdosing
Rosenstock J, Allison D, Birkenfeld AL, et al
How Oral Semaglutide Can Help During Perimenopause & Menopause When estrogen fluctuates and declines during perimenopause as you inch towards the end of your reproductive years, the effects are felt throughout the entire body
When expressed as the AUC, GLP-1(936) produced a small decrease (~30%) during hypoglycaemia (Fig
This is the unique component that separates retatrutide from everything else
So we didnt get into many of them here, but I talk about the thyroid cancer and the gastroparesis and the pancreatitis, all of that
